Patent US5344819A successfully refreshed from Google Patents.
US5344819A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical compositions for use in treating inflammation
Assignee: 722897 ONTARIO Ltd
•
Filing: 1992-02-03
•
Granted: 1994-09-06
•
Expires: 2012-02-03
Abstract
Abstract Inflammation in mammals is treated by administering anti-inflammatory agent complexed with corticosteroid binding globulin (CBG) that is produced by recombinant DNA-based techniques.
Inventors
- 👤 Geoffrey L. Hammond
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 15:47
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/575; A; A61; A61P; A61P29/00; A61K; A61K38/00; Y; Y02; Y02A; Y02A50/00; Y02A50/30
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
47 words
A pharmaceutical composition useful in treating inflammation in a mammal, said composition comprising CBG, an anti-inflammatory agent having an affinity constant for CBG between 0.1 and 10 nM at about 4° C. and physiological pH, and a pharmaceutically acceptable carrier, wherein said CBG is recombinant human CBG.
Claim 2
Dependent Claim
47 words
A pharmaceutical composition useful in treating inflammation in a mammal, said composition comprising CBG, an anti-inflammatory agent having an affinity constant for CBG between 0.1 and 10 nM at about 4° C. and physiological pH, and a pharmaceutically acceptable carrier, wherein said CBG is recombinant human CBG.
Claim 3
Dependent Claim
26 words
The composition according to claim 1 wherein the CBG is present in an amount sufficient to bind substantially all of the anti-inflammatory agent in the composition.
Claim 4
Dependent Claim
13 words
The composition according to claim 1 wherein said anti-inflammatory agent is a glucocorticoid.
Claim 5
Dependent Claim
16 words
The composition according to claim 3, wherein said glucocorticoid is selected from cortisol, prednisolone and methylprednisolone.
Claim 6
Dependent Claim
11 words
The composition according to claim 1 which is an injectable solution.
Claim 7
Dependent Claim
13 words
The composition according to claim 1 in a form suitable for topical administration.
Claim 8
Dependent Claim
10 words
The composition according to claim 6 which is an aerosol.
Claim 9
Independent Claim
55 words
A method for treating inflammation in a human patient, comprising the step of administering to the patient a pharmaceutical composition comprising CBG, an anti-inflammatory agent having an affinity constant for CBG between 0.1 and 10 nM at about 4° C. and physiological pH, and a pharmaceutically acceptable carrier, wherein said CBG is recombinant human CBG.
Claim 10
Independent Claim
55 words
A method for treating inflammation in a human patient, comprising the step of administering to the patient a pharmaceutical composition comprising CBG, an anti-inflammatory agent having an affinity constant for CBG between 0.1 and 10 nM at about 4° C. and physiological pH, and a pharmaceutically acceptable carrier, wherein said CBG is recombinant human CBG.
Claim 11
Dependent Claim
13 words
The method according to claim 8 wherein said anti-inflammatory agent is a glucocorticoid.
Claim 12
Dependent Claim
17 words
The method according to claim 9 wherein said anti-inflammatory agent is selected from cortisol, prednisolone and methylprednisolone.
Claim 13
Dependent Claim
13 words
The method according to claim 8 wherein said composition is administered by injection.
Claim 14
Dependent Claim
12 words
The method according to claim 8 wherein said composition is administered topically.
Claim 15
Dependent Claim
13 words
The method according to claim 8 wherein said composition is administered by inhalation.
Claim 16
Dependent Claim
17 words
A pharmaceutical composition comprising recombinant human CBG, a stoichiometric excess of cortisol, and a pharmaceutically acceptable carrier.
Claim 17
Dependent Claim
17 words
A pharmaceutical composition comprising recombinant human CBG, a stoichiometric excess of cortisol, and a pharmaceutically acceptable carrier.
Claim 18
Dependent Claim
17 words
A composition as claimed in claim 1, wherein said recombinant CBG is produced in a bacterial cell.
Claim 19
Dependent Claim
16 words
A composition as claimed in claim 1, wherein said recombinant CBG is produced in E. coli.
Claim 20
Dependent Claim
17 words
A composition as claimed in claim 1, wherein said recombinant CBG is produced in a fungal cell.
Claim 21
Dependent Claim
17 words
A composition as claimed in claim 1, wherein said recombinant CBG is produced in a yeast cell.
References Cited (Backward Citations)
US4997814A
Cited
US5086039A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-09-05 | 1998-03-07 | 1998-09-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-09-05 | 2002-03-07 | 2002-09-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-09-05 | 2006-03-07 | 2006-09-06 | $7700.00 | Window Closed / Lapsed |